NCT04706832View on ClinicalTrials.gov

Thoracic Splanchnic Magnetic Neuromodulation Therapy (ThorS-MagNT) for Grade 3 Diabetic Gastroparesis: Pilot Study

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 5, 2020

Primary Completion Date

October 30, 2022

Study Completion Date

December 30, 2022

Conditions
Diabetic Gastroparesis
Interventions
DEVICE

Thoracic Splanchnic Magnetic Neuromodulation Therapy

ThorS-MagNT is performed by low-frequency, low-intensity repetitive magnetic stimulation bilaterally around T7-8 intervertebral space twice a day for 5 days with a total 1200 magnetic stimulations per treatment session at 1 Hz.

Trial Locations (1)

30912

Augusta University, Augusta

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Augusta University

OTHER

NCT04706832 - Thoracic Splanchnic Magnetic Neuromodulation Therapy (ThorS-MagNT) for Grade 3 Diabetic Gastroparesis: Pilot Study | Biotech Hunter | Biotech Hunter